Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-A2-A0YJ-01A-11R-A109-07

— · E

56383da3-2bd4-564c-b794-f6ab997bcb6e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E
overall_survival_months
19

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.410
  • MYC_TARGETS_V2+0.410
  • G2M_CHECKPOINT+0.380
  • HYPOXIA+0.380
  • GLYCOLYSIS+0.370
  • MTORC1_SIGNALING+0.340
  • MITOTIC_SPINDLE+0.310
  • PROTEIN_SECRETION+0.300
  • MYC_TARGETS_V1+0.280
  • PI3K_AKT_MTOR_SIGNALING+0.260

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.630
  • INTERFERON_GAMMA_RESPONSE-0.480
  • ALLOGRAFT_REJECTION-0.350
  • COAGULATION-0.210
  • IL6_JAK_STAT3_SIGNALING-0.190
  • ANGIOGENESIS-0.180
  • COMPLEMENT-0.180
  • KRAS_SIGNALING_UP-0.170
  • XENOBIOTIC_METABOLISM-0.170
  • INFLAMMATORY_RESPONSE-0.160

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-GU-A42Q-01A-11R-A23W-07
bladder-landscape@3
——0.853
2SRR8518327
breast-umap@18
—E0.842
3TCGA-AR-A1AY-01A-21R-A12P-07
breast-umap@18
—E0.839
4TCGA-63-5128-01A-01R-1443-07
lung-landscapes@6
—cohortSQ20.836
5SRR8613740
breast-umap@18
—E0.835
6MNG495
mng-umap@100
——0.833
7TCGA-AR-A0TP-01A-11R-A084-07
breast-umap@18
—E0.833
8TCGA-51-4081-01A-01R-1100-07
lung-landscapes@6
—cohortSQ20.828
9TCGA-43-6770-01A-11R-1820-07
lung-landscapes@6
—cohortSQ20.826
10TCGA-85-8052-01A-11R-2247-07
lung-landscapes@6
—cohortSQ20.824

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.410Inavolisib— uncovered
MYC_TARGETS_V20.410Idelalisib— uncovered
G2M_CHECKPOINT0.380Inavolisib— uncovered
HYPOXIA0.380Idelalisib— uncovered
GLYCOLYSIS0.370Inavolisib— uncovered
MTORC1_SIGNALING0.340Inavolisib— uncovered
MITOTIC_SPINDLE0.310Inavolisib— uncovered
PROTEIN_SECRETION0.300Remibrutinib— uncovered
MYC_TARGETS_V10.280Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.260Inavolisib— uncovered
TGF_BETA_SIGNALING0.260Inavolisib— uncovered
HEDGEHOG_SIGNALING0.240Inavolisib— uncovered
SPERMATOGENESIS0.210Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.180Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.170Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.130Idelalisib— uncovered
MYOGENESIS0.090Inavolisib— uncovered
NOTCH_SIGNALING0.090Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.090Inavolisib— uncovered
KRAS_SIGNALING_DN0.080Remibrutinib— uncovered